Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry-Reference-Cited by-同舟云学术

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry

Published:2021-05-06 Issue: Volume: Page:
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Butzkueven Helmut¹^ORCID,Spelman Tim²,Horakova Dana³,Hughes Stella⁴⁵,Solaro Claudio⁶,Izquierdo Guillermo⁷,Kubala Havrdová Eva⁸,Grand'Maison Francois⁹,Prat Alexandre¹⁰,Girard Marc¹⁰,Hupperts Raymond¹¹,Onofrj Marco¹²,Lugaresi Alessandra¹³¹⁴,Taylor Bruce¹⁵,Giovannoni Gavin¹⁶,Kappos Ludwig¹⁷,Hauser Stephen L.¹⁸,Montalban Xavier¹⁹,Craveiro Licinio²⁰,Freitas Rita²⁰,Model Fabian²⁰,Overell James²⁰,Muros‐Le Rouzic Erwan²⁰,Sauter Annette²⁰,Wang Qing²⁰,Wormser David²⁰,Wolinsky Jerry S.²¹,

Affiliation:

1. Department of Neuroscience Central Clinical School Monash University Melbourne Victoria Australia

2. Department of Medicine and Melbourne Brain Centre The Royal Melbourne HospitalUniversity of Melbourne Melbourne Victoria Australia

3. Department of Neurology and Center of Clinical Neuroscience First Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

4. Department of Neurology Craigavon Area Hospital Craigavon UK

5. Belfast Health and Social Care Trust Belfast UK

6. CRRF "Mons. Luigi Novarese" Moncrivello (VC) Italy

7. Vithas Nisa Hospital Seville Spain

8. Department of Neurology and Center of Clinical Neuroscience General University Hospital and Charles University Prague Czech Republic

9. Neuro Rive‐Sud Quebec City Quebec Canada

10. CHUM and Universite de Montreal Montreal Quebec Canada

11. Zuyderland Ziekenhuis Sittard The Netherlands

12. University G. d'Annunzio Chieti Italy

13. IRCCS Istituto delle Scienze Neurologiche di BolognaUOSI Riabilitazione Sclerosi Multipla Bologna Italy

14. Dipartimento di Scienze Biomediche e Neuromotorie Università di Bologna Bologna Italy

15. Royal Hobart Hospital Hobart Tasmania Australia

16. Queen Mary University of London London UK

17. Research Center for Clinical Neuroimmunology and Neuroscience and MS Center University Hospital Basel and University of Basel Basel Switzerland

18. University of California San Francisco California USA

19. Department of Neurology–Neuroimmunology Centre d'Esclerosi Múltiple de Catalunya (Cemcat) Hospital Universitari Vall d'Hebron Barcelona Spain

20. F. Hoffmann–La Roche Ltd Basel Switzerland

21. McGovern Medical School The University of Texas Health Science Center at Houston (UTHealth) Houston Texas USA

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.14824

Reference15 articles.

1. Primary‐progressive multiple sclerosis;Miller DH;Lancet Neurol,2007

2. Patient preferences for attributes of multiple sclerosis disease‐modifying therapies: development and results of a ratings‐based conjoint analysis;Wilson LS;Int J MS Care,2015

3. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS);Kurtzke JF;Neurology,1983

4. New insights into the burden and costs of multiple sclerosis in Europe;Kobelt G;Mult Scler,2017

5. Maintenance of long‐lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice;DiLillo DJ;J Immunol,2008

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Co-supplementation of synbiotics and anti-inflammatory-antioxidant rich diet in patients with progressive forms of multiple sclerosis: A single-center, randomized clinical trial;Mediterranean Journal of Nutrition and Metabolism;2024-02-01

2. Ocrelizumab in highly disabled progressive multiple sclerosis patients;Multiple Sclerosis and Related Disorders;2024-02

3. A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis;International Immunopharmacology;2023-07

4. Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal;PharmacoEconomics - Open;2022-12-01

5. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis;JAMA Neurology;2022-09-01